FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313656031> ?p ?o ?g. }

• W4313656031 endingPage "103270" @default.
• W4313656031 startingPage "103270" @default.
• W4313656031 abstract "It is now accepted that immune tolerance disorders caused by inadequate Treg cell function or number are important factors in the development and progression of rheumatic diseases. There is increasing evidence that ld IL-2 treatment increases the proportion of Treg cells in patients' peripheral blood, but this conclusion is still controversial. Here, we performed a meta-analysis of reports documenting the proportion of Treg cells and the rate of adverse events in patients with rheumatic disease before and after the administration of ld IL-2 to better understand its effect and safety on Treg cells in the field of rheumatic diseases.We systematically searched PubMed, Embase, Scopus, Cochrane Library, and Web of science databases up to 15th November 2022 and identified studies that reported the proportion of peripheral blood Treg cells before and after ld IL-2 treatment in patients with rheumatic disease. Random-effects model was used to perform a meta-analysis of Treg cell proportions before and after ld IL-2 administration, and a meta-regression analysis was performed to explore heterogeneity. Inconsistency was evaluated using the I-squared index (I2), and publication bias was assessed by examining funnel plot asymmetry using the Egger tests.Eighteen studies involving 1608 patients were included in the meta-analysis. The proportion of Treg cells in peripheral blood of these patients increased significantly after receiving ld IL-2 treatment [1.07 (95% CI 0.86,1.27), p < 0.001, I2 = 67.3%]. Next, Meta-regression was performed for 5 variables including publish year, disease type, trail type and dosage and duration of the medication. The results suggest that these variables do not lead to high heterogeneity. (p = 0.698, 0.267, 0.502, 0.843, 0.560, respectively). And finally, statistical analysis showed no difference in adverse reactions between ld IL-2 group and control group in treatment [1.06 (95% CI 0.86,1.31), p = 0.586, I2 = 53.8%], which is unreliable because the data is so small.Ld IL-2 does increase the proportion of peripheral blood Treg cells in patients with rheumatism, and single and cumulative doses must be considered when using ld IL-2. In addition, more studies on the safety of ld IL-2 are urgently needed." @default.
• W4313656031 created "2023-01-07" @default.
• W4313656031 creator A5019018136 @default.
• W4313656031 creator A5047508906 @default.
• W4313656031 creator A5047810076 @default.
• W4313656031 creator A5049264813 @default.
• W4313656031 creator A5052960352 @default.
• W4313656031 creator A5053838580 @default.
• W4313656031 creator A5079526895 @default.
• W4313656031 date "2023-03-01" @default.
• W4313656031 modified "2023-10-16" @default.
• W4313656031 title "Low-dose interleukin-2 treatment increases the proportion of regulatory T cells in patients with rheumatic diseases: A meta-analysis" @default.
• W4313656031 cites W1967046314 @default.
• W4313656031 cites W1970246068 @default.
• W4313656031 cites W2291801226 @default.
• W4313656031 cites W2477823035 @default.
• W4313656031 cites W2808858860 @default.
• W4313656031 cites W2830145191 @default.
• W4313656031 cites W2887245816 @default.
• W4313656031 cites W2901041673 @default.
• W4313656031 cites W2912012533 @default.
• W4313656031 cites W2973404796 @default.
• W4313656031 cites W2982218448 @default.
• W4313656031 cites W3048568671 @default.
• W4313656031 cites W3085268199 @default.
• W4313656031 cites W3088900464 @default.
• W4313656031 cites W3095585388 @default.
• W4313656031 cites W3109320617 @default.
• W4313656031 cites W3115066413 @default.
• W4313656031 cites W3142178656 @default.
• W4313656031 cites W3153639242 @default.
• W4313656031 cites W3157817659 @default.
• W4313656031 cites W3159215868 @default.
• W4313656031 cites W3182131317 @default.
• W4313656031 cites W3183662835 @default.
• W4313656031 cites W3197321410 @default.
• W4313656031 cites W3198610907 @default.
• W4313656031 cites W3201702469 @default.
• W4313656031 cites W3207980966 @default.
• W4313656031 cites W4210401235 @default.
• W4313656031 cites W4210609407 @default.
• W4313656031 cites W4220687170 @default.
• W4313656031 cites W4221002279 @default.
• W4313656031 cites W4223485964 @default.
• W4313656031 cites W4282930531 @default.
• W4313656031 cites W4283120340 @default.
• W4313656031 cites W4285417818 @default.
• W4313656031 cites W4286792112 @default.
• W4313656031 cites W4295940398 @default.
• W4313656031 cites W4297859086 @default.
• W4313656031 cites W4298144985 @default.
• W4313656031 cites W4308861908 @default.
• W4313656031 cites W4309362680 @default.
• W4313656031 doi "https://doi.org/10.1016/j.autrev.2023.103270" @default.
• W4313656031 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36627065" @default.
• W4313656031 hasPublicationYear "2023" @default.
• W4313656031 type Work @default.
• W4313656031 citedByCount "1" @default.
• W4313656031 crossrefType "journal-article" @default.
• W4313656031 hasAuthorship W4313656031A5019018136 @default.
• W4313656031 hasAuthorship W4313656031A5047508906 @default.
• W4313656031 hasAuthorship W4313656031A5047810076 @default.
• W4313656031 hasAuthorship W4313656031A5049264813 @default.
• W4313656031 hasAuthorship W4313656031A5052960352 @default.
• W4313656031 hasAuthorship W4313656031A5053838580 @default.
• W4313656031 hasAuthorship W4313656031A5079526895 @default.
• W4313656031 hasConcept C126322002 @default.
• W4313656031 hasConcept C197934379 @default.
• W4313656031 hasConcept C203014093 @default.
• W4313656031 hasConcept C2776478404 @default.
• W4313656031 hasConcept C2779134260 @default.
• W4313656031 hasConcept C2780439572 @default.
• W4313656031 hasConcept C71924100 @default.
• W4313656031 hasConcept C82605166 @default.
• W4313656031 hasConcept C8891405 @default.
• W4313656031 hasConcept C95190672 @default.
• W4313656031 hasConceptScore W4313656031C126322002 @default.
• W4313656031 hasConceptScore W4313656031C197934379 @default.
• W4313656031 hasConceptScore W4313656031C203014093 @default.
• W4313656031 hasConceptScore W4313656031C2776478404 @default.
• W4313656031 hasConceptScore W4313656031C2779134260 @default.
• W4313656031 hasConceptScore W4313656031C2780439572 @default.
• W4313656031 hasConceptScore W4313656031C71924100 @default.
• W4313656031 hasConceptScore W4313656031C82605166 @default.
• W4313656031 hasConceptScore W4313656031C8891405 @default.
• W4313656031 hasConceptScore W4313656031C95190672 @default.
• W4313656031 hasFunder F4320321001 @default.
• W4313656031 hasFunder F4320336035 @default.
• W4313656031 hasFunder F4320336350 @default.
• W4313656031 hasFunder F4320336565 @default.
• W4313656031 hasIssue "3" @default.
• W4313656031 hasLocation W43136560311 @default.
• W4313656031 hasLocation W43136560312 @default.
• W4313656031 hasOpenAccess W4313656031 @default.
• W4313656031 hasPrimaryLocation W43136560311 @default.
• W4313656031 hasRelatedWork W2349688775 @default.
• W4313656031 hasRelatedWork W2392531270 @default.
• W4313656031 hasRelatedWork W2742455658 @default.

• next